Short answer
ResMed (RMD) filed its Q1 2026 10-Q quarterly report on May 1, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $1.4B (up 10.8% year over year) with net income of $399M.
Q1 2026 key financials · XBRL
- Revenue
- $1.4B
- +10.8% YoY · +0.6% QoQ
- Net income
- $399M
- +9.2% YoY · +1.6% QoQ
- Operating margin
- 34.9%
- Gross margin
- 62.2%
- EPS (diluted)
- $2.74
- +10.5% YoY · +2.2% QoQ
Source: XBRL data from the ResMed (RMD) Q1 2026 10-Q on SEC EDGAR. USD.
ResMed Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Share repurchases 673,418 shares in February at $259.87 average price
- 45,826,079 shares repurchased under program through March 31, 2026
- 8,889,934 shares remaining under authorized repurchase program
- Cumulative repurchases 11.1 million shares for $1.4 billion since 2014
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ResMed quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.